1. Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Mol Cancer Res. 2023;21(11):1142–7.
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
3. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141.
4. Brown A, Kumar S, Tchounwou PB. Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther. 2019;11(4):97.
5. Peña-Flores JA, Bermúdez M, Ramos-Payán R, Villegas-Mercado CE, Soto-Barreras U, Muela-Campos D, et al. Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma. Front Oncol. 2022;12:965628.
6. Nemati H, Fakhre-Taha M, Javanmard AR, Jahanbakhshi A, Mowla SJ, Soltani BM. LINC02381-ceRNA exerts its oncogenic effect through regulation of IGF1R signaling pathway in glioma. J Neurooncol. 2022;158(1):1–13.
7. Liang J, Zhao Z, Xie Y, Lai D, Okereke IC, Velotta JB, et al. Identification and validation of LINC02381 as a biomarker associated with lymph node metastasis in esophageal squamous cell carcinoma. Translational Cancer Research. 2025;14(1):613-25.
8. Chen X, Zhang Z, Ma Y, Su H, Xie P, Ran J. LINC02381 promoted cell viability and migration via targeting miR-133b in cervical cancer cells. Cancer Manag Res. 2020:3971–9.
9. Wang X, Wu P, Zeng C, Zhu J, Zhou Y, Lu Y, et al. Long intergenic non-protein coding RNA 02381 promotes the proliferation and invasion of ovarian endometrial stromal cells through the miR-27b-3p/CTNNB1 Axis. Genes (Basel). 2022;13(3):433.
10. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.
11. Köberle B, Schoch S. Platinum complexes in colorectal cancer and other solid tumors. Cancers (Basel). 2021;13(9):2073.
12. Sun MY, Xu B, Wu QX, Chen WL, Cai S, Zhang H, et al. Cisplatin-resistant gastric cancer cells promote the chemoresistance of cisplatin-sensitive cells via the exosomal RPS3-mediated PI3K-Akt-Cofilin-1 signaling axis. Front Cell Dev Biol. 2021;9:618899.
13. Zhang Y, Ai H, Fan X, Chen S, Wang Y, Liu L. Knockdown of long noncoding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1. Biol Res. 2020;53:14.
14. Li Z, Niu H, Qin Q, Yang S, Wang Q, Yu C, et al. lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143/FOSL2-signaling pathway in ovarian cancer. Mol Ther Nucleic Acids. 2019;17:92–101.
15. Ye P, Feng L, Shi S, Dong C. The mechanisms of lncRNA-mediated multidrug resistance and the clinical application prospects of lncRNAs in breast cancer. Cancers (Basel). 2022;14(9):2101.
16. Du J, Chen F, Chen Z, Zhao W, Wang J, Zhou M. LncRNA LINC01664 promotes cancer resistance through facilitating homologous recombination-mediated DNA repair. DNA Repair (Amst). 2024;143:103770.
17. Zhu Y, Shen Y, Chen R, Li H, Wu Y, Zhang F, et al. KCNQ1OT1 lncRNA affects the proliferation, apoptosis, and chemoresistance of small cell lung cancer cells via the JAK2/STAT3 axis. Ann Transl Med. 2021;9(10):891.
18. Wang ZH, Wang JH, Wang KQ, Zhou Y, Wang J. LncRNA FEZF1-AS1 promoted chemoresistance, autophagy and epithelial-mesenchymal transition (EMT) through regulation of miR-25-3p/ITGB8 axis in prostate cancer. Eur Rev Med Pharmacol Sci. 2020;24(5):2420–30.
19. Liu M, Li H, Li X, Pan B, Zhang J, Pan Y, et al. A novel lncRNA FUAT1/TNS4 axis confers chemoresistance by suppressing reactive oxygen species-mediated apoptosis in gastric cancer. Antioxid Redox Signal. 2024;41(1–3):24–41.
20. Sun Y, Wang X, Bu X. LINC02381 contributes to cell proliferation and hinders cell apoptosis in glioma by transcriptionally enhancing CBX5. Brain Res Bull. 2021;176:121–9.